Comparative Pharmacology
Head-to-head clinical analysis: BLOXIVERZ versus RIVASTIGMINE.
Peer-Reviewed Evidence
Head-to-head clinical analysis: BLOXIVERZ versus RIVASTIGMINE.
BLOXIVERZ vs RIVASTIGMINE
Comparing the clinical profiles, pharmacokinetic behaviors, and safety indices of these two therapeutic agents.
BLOXIVERZ is a selective serotonin reuptake inhibitor (SSRI) that potentiates serotonergic activity in the central nervous system by inhibiting the reuptake of serotonin at the serotonin transporter (SERT), leading to increased extracellular serotonin levels.
Reversible acetylcholinesterase inhibitor that enhances cholinergic function by increasing the concentration of acetylcholine at synaptic sites. Also inhibits butyrylcholinesterase.
10 mg intravenously every 12 hours; may increase to 15 mg every 12 hours based on clinical response.
1.5 mg orally twice daily initially, titrated by 1.5 mg/dose every 2 weeks to maintenance dose of 3-6 mg twice daily. Alternatively, transdermal patch: 4.6 mg/24h initially, titrate to 9.5 mg/24h after 4 weeks, then 13.3 mg/24h if tolerated.
None Documented
None Documented
Clinical Note
moderateRivastigmine + Dronedarone
"Rivastigmine may increase the bradycardic activities of Dronedarone."
Clinical Note
moderateRivastigmine + Nicotine
"The risk or severity of adverse effects can be increased when Rivastigmine is combined with Nicotine."
Clinical Note
moderateRivastigmine + Amiodarone
"Rivastigmine may increase the bradycardic activities of Amiodarone."
Clinical Note
moderateRivastigmine + Crizotinib
Terminal half-life 18 hours (range 14-22 h); clinical: steady state in ~3.5 days, dosing adjustments needed in renal impairment.
Terminal half-life ~1.5 h (oral, transdermal); clinical context: due to prolonged binding to acetylcholinesterase (AChE), effective half-life for AChE inhibition is ~10 h; steady state reached in 6-12 weeks.
Renal: 60% unchanged; Biliary/Fecal: 30% as metabolites; 10% other routes.
Renal: ~97% total (mostly metabolites, <1% unchanged); fecal: negligible; biliary: minor.
Category C
Category C
Cholinesterase Inhibitor
Cholinesterase Inhibitor
"Rivastigmine may increase the bradycardic activities of Crizotinib."